ustekinumab

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

Miguel Regueiro, MD, sat down with GEN to talk about some of his favorite studies focused on treating IBD.

NOVEMBER 19, 2024

In this edition of The Regueiro Report, I highlight a head-to-head comparison of two drugs and another study ...

OCTOBER 16, 2024

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

The FDA has approved ustekinumab-aauz (Otulfi, Fresenius Kabi/Formycon), a biosimilar to ustekinumab (Stelara, ...

OCTOBER 7, 2024

The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...

SEPTEMBER 5, 2024

Guselkumab induced higher levels of clinical and endoscopic remission than placebo and ustekinumab in the GALAXI ...

AUGUST 23, 2024

Both studies in this month’s The Regueiro Report are about interleukin inhibitors: risankizumab and ...

JULY 16, 2024

In this installment of Expert Picks from DDW 2024, Anisa Shaker, MD, discusses five of her favorite abstracts and ...

JULY 12, 2024

Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...

JULY 3, 2024

Digestive Disease Week 2024 was overflowing with research on all GI topics.

MAY 30, 2024

The standard approach to randomized clinical trials for moderate to severe IBD causes harm to participants, ...

MAY 21, 2024